<code id='FD170557E2'></code><style id='FD170557E2'></style>
    • <acronym id='FD170557E2'></acronym>
      <center id='FD170557E2'><center id='FD170557E2'><tfoot id='FD170557E2'></tfoot></center><abbr id='FD170557E2'><dir id='FD170557E2'><tfoot id='FD170557E2'></tfoot><noframes id='FD170557E2'>

    • <optgroup id='FD170557E2'><strike id='FD170557E2'><sup id='FD170557E2'></sup></strike><code id='FD170557E2'></code></optgroup>
        1. <b id='FD170557E2'><label id='FD170557E2'><select id='FD170557E2'><dt id='FD170557E2'><span id='FD170557E2'></span></dt></select></label></b><u id='FD170557E2'></u>
          <i id='FD170557E2'><strike id='FD170557E2'><tt id='FD170557E2'><pre id='FD170557E2'></pre></tt></strike></i>

          focus

          focus

          author:focus    Page View:88

          Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

          Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

          advertisement

          You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study
          Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

          AdobeAcadiaPharmaceuticalssaidMondaythatitsapprovedmedicinecalledNuplazidfailedtoimprovethesocialand

          read more
          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more

          Drug firms test therapies to halt Alzheimer’s before symptoms arise

          SinceFebruary2022,AstridaSchaefferhasdrivenabout160milesroundtripeveryotherweektoBrighamandWomen’sHo